ArticleInternational journal of clinical and experimental pathology2018
Low nuclear zinc finger and BTB domain containing 7A expression is an independent prognostic factor for recurrence-free survival in invasive ductal carcinoma of the breast.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of zinc finger and BTB domain containing 7A (ZBTB7A) in oncogenesis has been shown to be context-dependent, participating in pro-oncogenic or oncosuppressive mechanisms by directly regulating gene transcription or by interacting with other regulatory proteins. Alterations in ZBTB7A expression have been associated with worse prognosis. We examined ZBTB7A protein expression in breast carcinoma tissue samples and analyzed its clinical and prognostic significance. Tissue microarray blocks from 196 cases of invasive ductal carcinoma (IDC) were immunostained and <65% positively stained tumor cell nuclei were defined as low ZBTB7A expression. Of 196 IDC cases, 120 (61.2%) showed low ZBTB7A expression. Low nuclear ZBTB7A expression was associated with larger tumor size, higher histological grade, estrogen receptor negativity, progesterone receptor negativity, triple negativity, and recurrence. Cytoplasmic ZBTB7A expression was not associated with any clinicopathological characteristics. In univariate survival analysis, nuclear ZBTB7A expression did not affect overall or recurrence-free survival. However, multivariate survival analysis revealed that ZBTB7A independently predicted recurrence-free survival of IDC patients. Reduced ZBTB7A expression is associated with aggressive oncogenic behavior of IDC. ZBTB7A expression may be a novel prognostic biomarker for predicting recurrence-free survival of IDC patients.
Indexed as
Identifiers
31938331PMC6958227W2944960253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.